dalteparin has been researched along with pyrazines in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alkan, M; Demirkol, MA; Dinc, V; Esatoglu, SN; Kamat, S; Kostek, ME; Sargin Altunok, E; Satici, C; Toprak, ID; Yazla, S | 1 |
| Daye, M; Oltulu, P | 1 |
2 other study(ies) available for dalteparin and pyrazines
| Article | Year |
|---|---|
Comparison of demographic and clinical characteristics of hospitalized COVID-19 patients with severe/critical illness in the first wave versus the second wave.
Topics: Aged; Amides; Antibodies, Monoclonal, Humanized; Azithromycin; C-Reactive Protein; Comorbidity; COVID-19; COVID-19 Drug Treatment; Critical Care; Drug Combinations; Enoxaparin; Female; Hospital Mortality; Hospitalization; Humans; Hydroxychloroquine; Interleukin 1 Receptor Antagonist Protein; Lopinavir; Male; Methylprednisolone; Middle Aged; Pyrazines; Retrospective Studies; Ritonavir; SARS-CoV-2; Severity of Illness Index; Treatment Outcome; Turkey | 2022 |
An AGEP case due to COVİD-19 or favipiravir or enoxaparin.
Topics: Amides; COVID-19; Enoxaparin; Humans; Pyrazines; SARS-CoV-2 | 2022 |